A novel biological target for the treatment of psoriatic arthritis.
about
Secukinumab for ankylosing spondylitis and psoriatic arthritisBeyond TNF Inhibitors: New Pathways and Emerging Treatments for Psoriatic Arthritis.Therapeutic targeting of Toll-like receptors: a review of Toll-like receptors and their signaling pathways in psoriasis.Therapeutic depletion of myeloid lineage leukocytes by adsorptive apheresis for psoriatic arthritis: Efficacy of a non-drug intervention for patients refractory to pharmacologics.
P2860
A novel biological target for the treatment of psoriatic arthritis.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
A novel biological target for the treatment of psoriatic arthritis.
@en
A novel biological target for the treatment of psoriatic arthritis.
@nl
type
label
A novel biological target for the treatment of psoriatic arthritis.
@en
A novel biological target for the treatment of psoriatic arthritis.
@nl
prefLabel
A novel biological target for the treatment of psoriatic arthritis.
@en
A novel biological target for the treatment of psoriatic arthritis.
@nl
P2860
P356
P1433
P1476
A novel biological target for the treatment of psoriatic arthritis.
@en
P2093
Antonio Spadaro
Monica Montepaone
P2860
P304
P356
10.2217/IMT.14.39
P577
2014-01-01T00:00:00Z